title: Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine.
abstract: Levels of kynurenic acid (KYNA), an endogenous α7 nicotinic acetylcholine receptor (α7nAChR) antagonist, are elevated in the brain of patients with schizophrenia (SZ) and might contribute to the pathophysiology and cognitive deficits seen in the disorder. As developmental vulnerabilities contribute to the etiology of SZ, we determined, in rats, the effects of perinatal increases in KYNA on brain chemistry and cognitive flexibility. KYNA's bioprecursor l-kynurenine (100mg/day) was fed to dams from gestational day 15 to postnatal day 21 (PD21). Offspring were then given regular chow until adulthood. Control rats received unadulterated mash. Brain tissue levels of KYNA were measured at PD2 and PD21, and extracellular levels of KYNA and glutamate were determined by microdialysis in the prefrontal cortex in adulthood (PD56-80). In other adult rats, the effects of perinatal l-kynurenine administration on cognitive flexibility were assessed using an attentional set-shifting task. l-Kynurenine treatment raised forebrain KYNA levels ∼3-fold at PD2 and ∼2.5-fold at PD21. At PD56-80, extracellular prefrontal KYNA levels were moderately but significantly elevated (+12%), whereas extracellular glutamate levels were not different from controls. Set-shifting was selectively impaired by perinatal exposure to l-kynurenine, as treated rats acquired the discrimination and intra-dimensional shift at the same rate as controls, yet exhibited marked deficits in the initial reversal and extra-dimensional shift. Acute administration of the α7nAChR-positive modulator galantamine (3.0mg/kg, i.p.) restored performance to control levels. These results validate early developmental exposure to l-kynurenine as a novel, naturalistic animal model for studying cognitive deficits in SZ.
authors: Department of Psychology, The Ohio State University, Columbus, OH, USA; Department of Neuroscience, The Ohio State University, Columbus, OH, USA.
authors: K S
authors: KS
authors: Alexander
authors: A
authors: A
authors: Pocivavsek
authors: H-Q
authors: HQ
authors: Wu
authors: M L
authors: ML
authors: Pershing
authors: R
authors: R
authors: Schwarcz
authors: J P
authors: JP
authors: Bruno
mesh_terms: D000818:Animals; D001288:Attention / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D003071:Cognition / Q000187:drug effects*; D005260:Female; D005702:Galantamine / Q000494:pharmacology*; D018698:Glutamic Acid / Q000378:metabolism; D007736:Kynurenic Acid / Q000378:metabolism*; D007737:Kynurenine / Q000494:pharmacology*; D008297:Male; D018697:Nootropic Agents / Q000494:pharmacology*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D012718:Set, Psychology
chemical_list: D018697:Nootropic Agents; D005702:Galantamine; D007737:Kynurenine; D018698:Glutamic Acid; D007736:Kynurenic Acid
references: Schizophr Bull. 2011 Mar;37(2):284-90
references: 21134972
references: J Neurosci. 2002 May 1;22(9):3708-19
references: 11978847
references: Neuropharmacology. 2010 Dec;59(7-8):605-11
references: 20732335
references: Schizophr Bull. 2007 May;33(3):797-804
references: 16920787
references: Psychopharmacology (Berl). 2011 Aug;216(4):525-35
references: 21384103
references: J Psychopharmacol. 2009 May;23(3):287-94
references: 18562404
references: Neurotox Res. 2006 Oct;10(2):131-48
references: 17062375
references: J Pharmacol Exp Ther. 2011 Jun;337(3):572-82
references: 21270133
references: Int Rev Neurobiol. 2007;78:69-108
references: 17349858
references: Neurosci Biobehav Rev. 2009 Jul;33(7):1061-79
references: 19442688
references: Am J Psychiatry. 2001 Jun;158(6):918-25
references: 11384900
references: Behav Neurosci. 2011 Dec;125(6):825-35
references: 22122146
references: Neuroreport. 1999 Jun 3;10(8):1779-82
references: 10501574
references: Neuropsychopharmacology. 2006 Feb;31(2):297-309
references: 16012531
references: Int J Neuropsychopharmacol. 2010 May;13(4):475-85
references: 19607757
references: Neurosci Lett. 2001 Nov 2;313(1-2):96-8
references: 11684348
references: J Neurosci. 2010 Oct 27;30(43):14552-9
references: 20980613
references: J Neurosci. 2000 Jun 1;20(11):4320-4
references: 10818167
references: Neuropsychopharmacology. 2011 Nov;36(12):2477-87
references: 21814184
references: CNS Drug Rev. 2002 Summer;8(2):159-76
references: 12177686
references: Nature. 2005 Apr 21;434(7036):1022-6
references: 15846347
references: Schizophr Bull. 2011 May;37(3):514-23
references: 21505118
references: Biol Psychiatry. 2006 Sep 15;60(6):530-3
references: 16806095
references: J Neurochem. 2001 Aug;78(4):842-53
references: 11520905
references: J Psychiatry Neurosci. 2012 Jan;37(1):53-7
references: 21693093
references: Biol Psychiatry. 2001 Oct 1;50(7):521-30
references: 11600105
references: Neurobiol Learn Mem. 2008 May;89(4):567-73
references: 18054257
references: Psychopharmacology (Berl). 2012 Apr;220(3):627-37
references: 22038535
references: Neuropsychopharmacology. 2012 Jan;37(1):4-15
references: 21956446
references: Schizophr Bull. 2000;26(1):119-36
references: 10755673
references: Arch Gen Psychiatry. 2011 Jul;68(7):665-74
references: 21727251
references: Schizophr Res. 2011 May;128(1-3):7-14
references: 21353485
references: J Psychiatry Neurosci. 2001 Mar;26(2):123-30
references: 11291529
references: Neuroscience. 2010 Sep 15;169(4):1848-59
references: 20600676
references: J Neurosci. 2001 Oct 1;21(19):7463-73
references: 11567036
references: Biol Psychiatry. 2006 Jul 15;60(2):115-22
references: 16843094
references: Brain Res Brain Res Rev. 1999 Nov;30(3):219-35
references: 10567725
references: Schizophr Res. 2007 May;92(1-3):168-80
references: 17399952
references: Neurobiol Learn Mem. 2008 Sep;90(2):339-46
references: 18490183
references: Biol Psychiatry. 2008 Jul 1;64(1):34-9
references: 18374901
references: Schizophr Bull. 2011 Nov;37(6):1147-56
references: 21036897
references: Biol Psychiatry. 1999 Jul 1;46(1):56-72
references: 10394474
references: Behav Brain Res. 2009 Aug 12;201(2):325-31
references: 19428652
references: J Mol Neurosci. 2010 Jan;40(1-2):204-10
references: 19690987
references: Neuropsychopharmacology. 2011 Oct;36(11):2357-67
references: 21796108
references: Neuroscience. 1999;94(3):767-74
references: 10579567
references: Behav Brain Res. 2003 Nov 30;146(1-2):97-103
references: 14643463
references: Biol Psychiatry. 2011 Jan 1;69(1):19-27
references: 20970118
references: Neurosci Biobehav Rev. 2003 Jan-Mar;27(1-2):33-44
references: 12732221
references: Schizophr Res. 2011 Dec;133(1-3):156-8
references: 21907545
references: Eur J Neurosci. 2012 May;35(10):1605-12
references: 22515201
references: Neuropsychopharmacology. 2009 Dec;34(13):2710-20
references: 19693002
references: Biol Psychiatry. 2004 Aug 15;56(4):255-60
references: 15312813
references: Behav Neurosci. 2003 Aug;117(4):728-37
references: 12931958
references: Eur J Neurosci. 2009 Feb;29(3):529-38
references: 19187269
references: Neuroreport. 1996 Aug 12;7(12):2051-5
references: 8905723
references: Psychiatry Res. 2004 Dec 30;129(3):229-39
references: 15661316
references: Behav Neurosci. 2006 Apr;120(2):298-306
references: 16719694
references: Schizophr Bull. 2012 Jun;38(4):769-78
references: 21172906
references: Brain Res. 2006 Feb 16;1073-1074:25-37
references: 16448631
references: Eur J Neurosci. 2007 Apr;25(8):2504-13
references: 17445246
references: Am J Psychiatry. 2008 Jan;165(1):82-9
references: 17986678
references: Schizophr Res. 2003 Dec 15;65(2-3):87-94
references: 14630301
references: Am J Psychiatry. 2001 Jul;158(7):1105-13
references: 11431233
references: Psychophysiology. 1987 Jul;24(4):479-86
references: 3615759
references: Brain Res. 2005 Feb 8;1033(2):186-93
references: 15694923
references: Curr Opin Investig Drugs. 2006 Jul;7(7):608-13
references: 16869112
references: Cogn Neuropsychiatry. 2009;14(4-5):277-98
references: 19634031
references: J Mol Neurosci. 2010 Jan;40(1-2):185-95
references: 19680823
references: Clin Ther. 2005;27 Suppl A:S8-15
references: 16198200
references: J Chromatogr. 1988 Sep 9;430(2):376-80
references: 3235510
references: Schizophr Res. 2009 Jul;112(1-3):104-13
references: 19464854
references: J Pharmacol Exp Ther. 2007 Jul;322(1):48-58
references: 17446300
references: J Neurosci Methods. 2009 Dec 15;185(1):66-9
references: 19761795
references: Stress. 2011 May;14(3):262-72
references: 21294659
references: Schizophr Bull. 2009 Jan;35(1):182-96
references: 19074499